TrialBreast cancer research : BCR2019

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.

William Jacot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.